Genedrive (GB:GDR) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genedrive PLC’s CYP2C19-ID Kit has been endorsed by the UK’s National Institute for Health and Care Excellence (NICE) as the preferred point-of-care test for guiding clopidogrel treatment in stroke patients within the NHS. With its UKCA certification and completed DEVOTE clinical phase, Genedrive is set to commercialize the product in the UK and Middle East. The test, which rapidly identifies genetic variants using a cheek swab, promises to improve patient outcomes by enabling personalized treatment plans in emergency healthcare situations.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
